Long-term effects of ticlopidine on fibrinogen and haemorheology in patients with peripheral arterial disease

Palareti, Gualtiero; Poggi, M; Torricelli, Paola; Balestra, Vincenzo; Coccheri, S.

doi:10.1016/0049-3848(88)90134-x

Cited by 34 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a single-blind cross-over study, ticlopidine significantly reduced platelet adhesion to the subendothelium [111], and in a combined Canadian-American study, it effected a 30.2% reduction in stroke, myocardial infarction or vascular death when compared to placebo [112]. Like pentoxyfylline, it has also been shown to reduce the incidence of intermit tent claudication [113][114][115], Although originally reported to reduce intimal hyper plasia [116.117], more recent studies have not demonstrated any benefit [118]. In coronary artery bypass grafts, a ran domized placebo-controlled study of 175 patients [119] found no real difference in patency when compared to aspirin.…”

Section: Antiplatelet Agentsmentioning

confidence: 99%

Pharmacologic Intervention to Prevent Hemodialysis Vascular Access Thrombosis

Diskin

Stokes

Pennell

1993

Nephron

View full text Add to dashboard Cite

Section: Antiplatelet Agentsmentioning

confidence: 99%

Pharmacologic Intervention to Prevent Hemodialysis Vascular Access Thrombosis

Diskin

Stokes

Pennell

1993

Nephron

View full text Add to dashboard Cite

“…A subsequent study, performed by some of us [11], showed that a long-term (21 months) therapy with ti clopidine was able to significantly reduce not only plasma fibrinogen, but also other haemorheological parameters (haematocrit, plasma and whole blood viscosities at high and low shear rate) in claudicant patients.…”

Section: Discussionmentioning

confidence: 99%

“…In a previous study, we found that PRV patients with overt vascular disease, or with vascular risk fac tors, although receiving cytoreductive treatment, still showed altered haemorheological patterns, mainly due to plasma hyperviscosity and hyperfibrinogen emia [5]. Ticlopidine, an antithrombotic agent which acts mainly but not exclusively as an antiplatelet drug [6], has been shown to lower plasma fibrinogen, and plasma and whole blood viscosity in patients with vascular disease or diabetes mellitus [7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Ticlopidine Lowers Plasma Fibrinogen in Patients with Polycythaemia Rubra Vera and Additional Thrombotic Risk Factors

Finelli

Palareti²,

Poggi³

et al. 1991

Acta Haematol

View full text Add to dashboard Cite

Thirty-seven patients affected by polycythaemia rubra vera (PRV) and with at least one additional thrombotic risk factor (overt vascular disease, diabetes mellitus, treated hypertension, smoking habit, plasma hyperviscosity, hyperfibrinogenemia) were enrolled in a double-blind randomized placebo-controlled study, and 18 were given ticlopidine 250 mg, b.i.d., for 60 days. All the patients had previously been submitted to cytoreduction, and PRV was under control in all cases at the start of the study. During the study, the haematological parameters were controlled every 15 days, and venesection was performed if haematocrit was > 46%. Whole blood viscosity, at low and high shear rates, plasma viscosity, and fibrinogen were measured on days 0 and 60. In the ticlopidine group, we recorded a significant 13.14% reduction of the mean fibrinogen level after treatment (390 ± 63 vs. 449 ± 97 mg/dl, p < 0.01). All the other haemorheological parameters were not significantly modified by ticlopidine treatment, nor were there significant modifications recorded in the placebo group. Our study shows that ticlopidine may reduce a probable thrombotic risk factor (hyperfibrinogenemia) in PRV patients.

show abstract

“…(Feliste et al, 1987;Gachet et al, 1990) and may also inhibit intracellular calcium mobilisation (Derian et al, 1988). Ticlopidine also decreases plasma fibrinogen and haematocrit (Palareti et al, 1988). The antithrombotic potential of several of these agents has been evaluated in studies in both animals and human subjects.…”

Section: (Iii) Measurement and Characterisationmentioning

confidence: 99%